I-Mab’s (IMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of I-Mab (NASDAQ:IMAB) in a report published on Tuesday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.

I-Mab Stock Performance

NASDAQ:IMAB opened at $1.11 on Tuesday. The firm has a 50-day simple moving average of $1.22 and a 200-day simple moving average of $1.58. I-Mab has a one year low of $0.99 and a one year high of $2.54.

I-Mab (NASDAQ:IMAB) last posted its quarterly earnings data on Wednesday, August 28th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.44. On average, research analysts forecast that I-Mab will post -0.38 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in I-Mab stock. Bank of Montreal Can purchased a new stake in shares of I-Mab (NASDAQ:IMAB) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 244,875 shares of the company’s stock, valued at approximately $453,000. Bank of Montreal Can owned approximately 0.30% of I-Mab at the end of the most recent quarter. 38.38% of the stock is owned by institutional investors.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.